EXISECRET

UnknownPhase NA

Exercise and GLP-1 RA on Insulin Secretion

Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes

Lead sponsor

University of Copenhagen

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI 28-35

Primary endpoint

•Insulin secretion

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04383197

Org study IDH-19008233

Timeline

Milestones

Study start2019-12-10actual

Study first posted2020-05-12actual

Last update posted2021-02-11actual

Primary completion2021-08estimated (month precision)

Study completion2022-08estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 2 diabetes

•BMI 28-35

•Moderately preserved insulin secretory capacity (determined by glucagon test)

Exclusion criteria

•Insulin treatment

•Hypertension grade 3

•Heart disease

•Medical history with pancreatitis

•Diagnosed with neuropathy

•Excessive alcohol consumption

•Any condition that would interfere with the protocol.

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Other clinical outcomes

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Body composition

Time frame:Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment

change from baseline, improvement

Glycemic / diabetes

6 endpoints

Primary/protocol endpoint/low confidence

Insulin secretion

Time frame:Change from baseline insulin secretion after Exercise intervention(12 weeks).

change from baseline, improvement

Primary/protocol endpoint

Insulin secretion

Time frame:Change from baseline insulin secretion after 3 months of therapeutic semaglutide treatment

change from baseline, improvement

Primary/protocol endpoint

Insulin secretion

Time frame:Change from baseline insulin secretion after 3 months of combined exercise and therapeutic semaglutide treatment

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Insulin secretion

Time frame:Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment

descriptive, improvement

Secondary/protocol endpoint

insulin sensitivity

Time frame:Before and after (2 days) Exercise intervention(12 weeks). Before and after 3 months of therapeutic semaglutide treatment

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/protocol endpoint

Glucose homeostasis

Time frame:Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Cardiorespiratory fitness

Time frame:Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Changes in plasma bone markers

Time frame:Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism2023 Oct 18PMID37265222doi:10.1210/clinem/dgad326via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.